Editas Medicine, Inc. (EDIT)

Market Cap	190.87M
Revenue (ttm)	35.84M
Net Income (ttm)	-251.23M
Shares Out	83.71M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,462,985
Open	2.150
Previous Close	2.120
Day's Range	2.130 - 2.330
52-Week Range	0.910 - 6.050
Beta	2.10
Analysts	Buy
Price Target	6.20 (+171.93%)
Earnings Date	Aug 6, 2025

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 246
• Stock Exchange: NASDAQ
• Ticker Symbol: EDIT
• Website: https://www.editasmedicine.com

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $6.2, which is an increase of 171.93% from the latest price.

Price Target

$6.2

(171.93% upside)

Analyst Consensus: Buy